Lifeline for anemia patients: drug access extended for those seeing benefits
NCT ID NCT05221619
First seen Jan 05, 2026 · Last updated May 25, 2026 · Updated 22 times
Summary
This program offers ongoing access to the drug nipocalimab for people with warm autoimmune hemolytic anemia (wAIHA) who have already shown improvement in a previous study. Participants must have completed 28 weeks of treatment and be experiencing clinical benefit, such as increased hemoglobin levels. The goal is to maintain disease control without interruption.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WARM AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.